Camurus (CAMX) Stock Overview
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for CAMX from our risk checks.
CAMX Community Fair Values
Create NarrativeSee what 60 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Camurus AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 530.50 |
| 52 Week High | SEK 754.50 |
| 52 Week Low | SEK 430.80 |
| Beta | 0.50 |
| 1 Month Change | -4.76% |
| 3 Month Change | -0.38% |
| 1 Year Change | 3.82% |
| 3 Year Change | 79.71% |
| 5 Year Change | 164.59% |
| Change since IPO | 703.79% |
Recent News & Updates
Analysis Article • May 20
The Strong Earnings Posted By Camurus (STO:CAMX) Are A Good Indication Of The Strength Of The Business
Investors were underwhelmed by the solid earnings posted by Camurus AB (publ) ( STO:CAMX ) recently. Our analysis says...Analysis Article • May 15
Camurus AB (publ) Just Missed EPS By 29%: Here's What Analysts Think Will Happen Next
Camurus AB (publ) ( STO:CAMX ) missed earnings with its latest quarterly results, disappointing overly-optimistic...
Narrative Update • Apr 29
CAMX: 2026 Guidance And Earnings Outlook Will Drive Future Upside Potential
Analysts have trimmed their price target on Camurus to SEK770 from SEK814, reflecting updated views on fair value, discount rate and the balance between higher projected revenue growth and more moderate profit margins, with only a small adjustment to expected future P/E. What's in the News Camurus issued earnings guidance for 2026, setting expected revenues in a range of SEK 2.6b to SEK 2.9b (Key Developments).Recent updates
Analysis Article • May 20
The Strong Earnings Posted By Camurus (STO:CAMX) Are A Good Indication Of The Strength Of The Business
Investors were underwhelmed by the solid earnings posted by Camurus AB (publ) ( STO:CAMX ) recently. Our analysis says...Analysis Article • May 15
Camurus AB (publ) Just Missed EPS By 29%: Here's What Analysts Think Will Happen Next
Camurus AB (publ) ( STO:CAMX ) missed earnings with its latest quarterly results, disappointing overly-optimistic...Narrative Update • Apr 29
CAMX: 2026 Guidance And Earnings Outlook Will Drive Future Upside Potential
Analysts have trimmed their price target on Camurus to SEK770 from SEK814, reflecting updated views on fair value, discount rate and the balance between higher projected revenue growth and more moderate profit margins, with only a small adjustment to expected future P/E. What's in the News Camurus issued earnings guidance for 2026, setting expected revenues in a range of SEK 2.6b to SEK 2.9b (Key Developments).
Narrative Update • Apr 14
CAMX: 2026 Earnings Guidance Will Support Further Share Price Upside
Analysts have maintained their SEK 930 price target on Camurus, supported by updated forecasts that reflect slightly higher revenue growth, a marginally stronger profit margin, and a modestly lower future P/E assumption. What's in the News Camurus issued earnings guidance for 2026, with expected revenues in a range of SEK 2.6b to SEK 2.9b.
Narrative Update • Mar 31
CAMX: FDA Review Of Resubmitted NDA Will Drive Future Upside
Analysts have trimmed their 12 month price target for Camurus from SEK 660 to SEK 610, citing updated assumptions that include revised revenue growth, profit margin and future P/E expectations. What's in the News Camurus issued earnings guidance for 2026, with expected revenues of SEK 2.6b to SEK 2.9b and an operating result of SEK 0.9b to SEK 1.2b, framed against internal 2025 expectations (Key Developments).Narrative Update • Mar 17
CAMX: 2026 Guidance And US FDA Review Will Drive Future Upside
Analysts have kept their SEK 930 price target for Camurus unchanged, citing only minor adjustments in their assumptions for revenue growth, profit margin and future P/E as the main reasons for maintaining this level. What's in the News Camurus issued earnings guidance for 2026, with expected revenues of SEK 2.6b to SEK 2.9b and an operating result of SEK 0.9b to SEK 1.2b (Corporate guidance).Narrative Update • Mar 03
CAMX: Upcoming US And EU Launches Will Drive Future Upside Potential
Analysts have reset their price target on Camurus to SEK 930 from SEK 1,102, reflecting updated views on slightly higher forecast revenue growth, a modestly lower projected profit margin and a reduced future P/E multiple. What's in the News Camurus issued earnings guidance for 2026, expecting revenues of SEK 2.6b to SEK 2.9b and an operating result of SEK 0.9b to SEK 1.2b (Corporate guidance).Analysis Article • Feb 18
These Analysts Just Made A Sizeable Downgrade To Their Camurus AB (publ) (STO:CAMX) EPS Forecasts
One thing we could say about the analysts on Camurus AB (publ) ( STO:CAMX ) - they aren't optimistic, having just made...Narrative Update • Feb 17
CAMX: FDA Review And New Partnership Will Drive Future Upside
Analysts have kept their SEK 660 price target for Camurus unchanged, with updated assumptions pointing to higher forecast revenue growth and a higher future P/E, alongside a lower projected profit margin. What's in the News Camurus issued earnings guidance for 2026, with expected revenues of SEK 2.6b to SEK 2.9b and an operating result of SEK 0.9b to SEK 1.2b, both framed relative to 2025 levels in the company communication (Corporate guidance).Narrative Update • Feb 03
CAMX: Obesity Data And Resubmitted NDA Will Drive Future Upside Potential
Analysts have lifted their price target on Camurus from SEK 793.71 to SEK 814.17, citing updated assumptions around revenue growth, margin potential, and a lower future P/E multiple as key drivers of the change. What's in the News The U.S. FDA accepted Camurus' resubmitted New Drug Application for Oclaiz (CAM2029) for acromegaly treatment and set a PDUFA target action date of 10 June 2026, following an earlier Complete Response Letter related to a third party manufacturing facility (Key Developments).Narrative Update • Jan 19
CAMX: Guidance Cut Will Be Offset By Pipeline Progress And New Partnership
Analysts have kept their price target for Camurus steady at SEK 660, citing updated assumptions around revenue growth, a profit margin of 72.87% and a future P/E of 12.70 as key inputs to their valuation work. What's in the News The U.S. FDA accepted Camurus' resubmitted New Drug Application for Oclaiz (CAM2029) for acromegaly, with a PDUFA target action date of 10 June 2026.Narrative Update • Jan 05
CAMX: Revised Outlook Will Balance Guidance Cut With Pipeline And Partnership Progress
Analysts have trimmed their Camurus fair value estimate from SEK 690.00 to SEK 660.00, citing updated assumptions for the discount rate, revenue growth, profit margin and future P/E. What's in the News Camurus revised its 2025 earnings guidance, now expecting total revenue of SEK 2.3b to SEK 2.6b, compared with the previous range of SEK 2.7b to SEK 3.0b, while keeping profit before tax guidance at SEK 0.9b to SEK 1.2b (Key Developments).Narrative Update • Dec 22
CAMX: Positive Obesity Data Will Drive Future Upside Potential
Narrative Update on Camurus Analysts have modestly raised their price target on Camurus to reflect a fair value of approximately SEK 794 per share, citing sustained strong revenue growth expectations and robust long term profit margins as key drivers of the upward revision. What's in the News Reported positive topline Phase 1b results for CAM2056, a monthly FluidCrystal semaglutide, showing dose dependent reductions in body weight, A1c, and fasting glucose that were comparable to or exceeded weekly semaglutide, with similar or better efficacy in a shorter treatment period (Key Developments).Narrative Update • Dec 08
CAMX: Positive Obesity Data And New EU Launch Will Drive Upside
Analysts have modestly trimmed their price target on Camurus, lowering it by approximately SEK 7 to reflect slightly softer long term revenue growth and margin assumptions, partly offset by a higher expected future earnings multiple. What's in the News Positive topline Phase 1b data for monthly GLP 1 candidate CAM2056 showed dose dependent reductions in body weight, A1c, and fasting glucose that were comparable to or exceeded weekly semaglutide, with a favorable extended release profile suitable for monthly dosing (Key Developments) In the Phase 1b trial, CAM2056 10 mg achieved a mean weight loss of 9.3 percent at Day 85 versus 5.2 percent for weekly semaglutide, with statistically significant treatment difference, and similar weight reduction after 3 months as weekly semaglutide after 5 months (Key Developments) Camurus lowered its 2025 revenue guidance to SEK 2.3 billion to SEK 2.6 billion from SEK 2.7 billion to SEK 3.0 billion, while maintaining profit before tax guidance at SEK 0.9 billion to SEK 1.2 billion (Key Developments) Camurus launched Oczyesa, an octreotide subcutaneous depot for maintenance treatment of adults with acromegaly previously stabilized on somatostatin analogs, in Germany as the first EU market (Key Developments) Valuation Changes Fair Value: Trimmed slightly from SEK 800.86 to SEK 793.71, reflecting a modest downward revision in intrinsic value estimates.Analysis Article • Dec 08
Camurus AB (publ)'s (STO:CAMX) Intrinsic Value Is Potentially 69% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, Camurus fair value estimate is kr1,022 Camurus is estimated to...Narrative Update • Nov 24
CAMX: New European Launch And Regulatory Progress Will Drive Future Upside
Camurus's analyst price target has been slightly revised downward from SEK 801.17 to SEK 800.86. This change reflects updated assessments on growth and profitability expectations according to analysts.Analysis Article • Nov 19
Analysts Have Just Cut Their Camurus AB (publ) (STO:CAMX) Revenue Estimates By 11%
Market forces rained on the parade of Camurus AB (publ) ( STO:CAMX ) shareholders today, when the analysts downgraded...Analysis Article • Nov 09
Here's What Analysts Are Forecasting For Camurus AB (publ) (STO:CAMX) Following Its Earnings Miss
Camurus AB (publ) ( STO:CAMX ) just released its latest quarterly report and things are not looking great. It looks...Narrative Update • Nov 07
CAMX: European Market Launch And Regulatory Wins Will Drive Profitability Higher
Analysts have lowered their price target for Camurus from SEK 832.17 to SEK 801.17. They cite modestly higher discount rates and slower projected revenue growth, although the updated outlook includes improved profit margins.Analysis Article • Oct 19
If EPS Growth Is Important To You, Camurus (STO:CAMX) Presents An Opportunity
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Narrative Update • Sep 04
Global Expansion And Regulatory Approvals Will Transform Healthcare Delivery
With key metrics such as future P/E (16.49x) and net profit margin (54.67%) remaining stable, Camurus’s fair value assessment is unchanged, with the consensus analyst price target holding steady at SEK832.17. What's in the News Camurus received UK MHRA marketing authorization for Oczyesa® (octreotide subcutaneous depot) for maintenance treatment of adult acromegaly patients, following comprehensive clinical studies including two Phase 3 trials.Analysis Article • Jun 10
Should You Be Adding Camurus (STO:CAMX) To Your Watchlist Today?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analysis Article • May 23
There May Be Underlying Issues With The Quality Of Camurus' (STO:CAMX) Earnings
Last week's profit announcement from Camurus AB (publ) ( STO:CAMX ) was underwhelming for investors, despite headline...Analysis Article • May 08
There's No Escaping Camurus AB (publ)'s (STO:CAMX) Muted Revenues Despite A 27% Share Price Rise
Camurus AB (publ) ( STO:CAMX ) shares have had a really impressive month, gaining 27% after a shaky period beforehand...Analysis Article • Mar 09
Camurus AB (publ)'s (STO:CAMX) Popularity With Investors Is Under Threat From Overpricing
There wouldn't be many who think Camurus AB (publ)'s ( STO:CAMX ) price-to-sales (or "P/S") ratio of 19.2x is worth a...
New Narrative • Dec 30
Buvidal And Brixadi Expansion To Fuel Revenue Growth And Boost Profit Margins
Strong R&D pipeline and successful regulatory progress signal future revenue growth from new treatments entering various markets.Analysis Article • Dec 07
Camurus AB (publ)'s (STO:CAMX) P/S Is On The Mark
You may think that with a price-to-sales (or "P/S") ratio of 19x Camurus AB (publ) ( STO:CAMX ) is a stock to...Analysis Article • Nov 15
Investors Can Find Comfort In Camurus' (STO:CAMX) Earnings Quality
The market for Camurus AB (publ)'s ( STO:CAMX ) shares didn't move much after it posted weak earnings recently. We...Analysis Article • Nov 10
Camurus AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Investors in Camurus AB (publ) ( STO:CAMX ) had a good week, as its shares rose 2.5% to close at kr615 following the...Analysis Article • Aug 09
What Camurus AB (publ)'s (STO:CAMX) P/S Is Not Telling You
Camurus AB (publ)'s ( STO:CAMX ) price-to-sales (or "P/S") ratio of 24.3x might make it look like a sell right now...Analysis Article • Jul 19
Earnings Miss: Camurus AB (publ) Missed EPS By 11% And Analysts Are Revising Their Forecasts
Last week, you might have seen that Camurus AB (publ) ( STO:CAMX ) released its second-quarter result to the market...Analysis Article • Jul 12
We Ran A Stock Scan For Earnings Growth And Camurus (STO:CAMX) Passed With Ease
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analysis Article • May 02
Camurus AB (publ)'s (STO:CAMX) CEO Will Probably Have Their Compensation Approved By Shareholders
Key Insights Camurus to hold its Annual General Meeting on 8th of May CEO Fredrik Tiberg's total compensation includes...Analysis Article • Apr 19
Investors Appear Satisfied With Camurus AB (publ)'s (STO:CAMX) Prospects
There wouldn't be many who think Camurus AB (publ)'s ( STO:CAMX ) price-to-sales (or "P/S") ratio of 15.9x is worth a...Analysis Article • Feb 22
Camurus' (STO:CAMX) Strong Earnings Are Of Good Quality
Camurus AB (publ)'s ( STO:CAMX ) earnings announcement last week was disappointing for investors, despite the decent...Shareholder Returns
| CAMX | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 3.2% | 2.7% | 1.9% |
| 1Y | 3.8% | -8.2% | 12.3% |
Return vs Industry: CAMX exceeded the Swedish Pharmaceuticals industry which returned -9.9% over the past year.
Return vs Market: CAMX underperformed the Swedish Market which returned 9.9% over the past year.
Price Volatility
| CAMX volatility | |
|---|---|
| CAMX Average Weekly Movement | 5.8% |
| Pharmaceuticals Industry Average Movement | 7.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in SE Market | 13.2% |
| 10% least volatile stocks in SE Market | 3.7% |
Stable Share Price: CAMX has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: CAMX's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 274 | Fredrik Tiberg | www.camurus.com |
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and is under phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 for the treatment of pulmonary arterial hypertension, as well as in phase II clinical trial to treat Raynaud’s phenomenon.
Camurus AB (publ) Fundamentals Summary
| CAMX fundamental statistics | |
|---|---|
| Market cap | SEK 31.70b |
| Earnings (TTM) | SEK 682.13m |
| Revenue (TTM) | SEK 2.24b |
46.5x
P/E Ratio14.1x
P/S RatioIs CAMX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CAMX income statement (TTM) | |
|---|---|
| Revenue | SEK 2.24b |
| Cost of Revenue | SEK 154.01m |
| Gross Profit | SEK 2.09b |
| Other Expenses | SEK 1.40b |
| Earnings | SEK 682.13m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Jul 15, 2026
| Earnings per share (EPS) | 11.42 |
| Gross Margin | 93.13% |
| Net Profit Margin | 30.45% |
| Debt/Equity Ratio | 0% |
How did CAMX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/21 06:14 |
| End of Day Share Price | 2026/05/21 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Camurus AB (publ) is covered by 10 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |
| Gonzalo Artiach Castanon | Danske Bank |
| Kristofer Liljeberg-Svensson | DNB Carnegie |